A Randomized, DBPC, Multi-National Phase II/III Study of the Safety and Efficacy of Two Doses of Sublingual Immunotherapy (SLIT) Administered as Allergen-Based Tablets Once Daily to Adult Patients Suffering From HDM Allergic Rhinitis.

Trial Profile

A Randomized, DBPC, Multi-National Phase II/III Study of the Safety and Efficacy of Two Doses of Sublingual Immunotherapy (SLIT) Administered as Allergen-Based Tablets Once Daily to Adult Patients Suffering From HDM Allergic Rhinitis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs S 524101 (Primary)
  • Indications Hypersensitivity; Perennial allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Mar 2016 Results from this and other trial (Clinical trial profile-213251) presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 05 Mar 2016 Results presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2016 Annual Meeting, according to a Stallergenes BV media release.
    • 05 Mar 2016 Results published in a Stallergenes BV media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top